目的 探討雙黃連注射液聯(lián)合哌拉西林鈉他唑巴坦鈉治療社區(qū)獲得性肺炎的臨床效果。方法 選取2020年10月-2023年9月華北醫(yī)療健康集團(tuán)峰峰總醫(yī)院收治的86例社區(qū)獲得性肺炎患者,按隨機(jī)數(shù)字表法將所有患者分為對照組和治療組,每組各43例。對照組靜脈滴注注射用哌拉西林鈉他唑巴坦鈉,將4.5 g本品以稀釋液充分溶解后,立即加入100 mL5%葡萄糖注射液中,每次給藥時間 ≥ 30 min,2次/d。治療組在對照組治療基礎(chǔ)上靜脈滴注雙黃連注射液,按體質(zhì)量1 mL/kg加入250 mL 5%葡萄糖注射液中,1次/d。兩組療程均為7 d。觀察兩組臨床療效,比較兩組臨床表現(xiàn)消失時間及治療前后氧合指數(shù)(OI)、CURB-65評分、紅細(xì)胞沉降率(ESR)、中性粒細(xì)胞與淋巴細(xì)胞比值(NLR)及血清淀粉樣蛋白A(SAA)、降鈣素原(PCT)。結(jié)果 治療后,治療組總有效率是97.67%,顯著高于對照組的81.40%(P<0.05)。治療組發(fā)熱、咳嗽、咯痰、胸悶痛及肺部啰音消失時間較之對照組顯著縮短(P<0.05)。治療后,兩組OI均顯著增高,而CURB-65評分均顯著降低(P<0.05);且治療后,治療組OI顯著高于對照組,CURB-65評分顯著低于對照組(P<0.05)。治療后,兩組ESR、NLR及血清SAA、PCT水平治療后均顯著下降(P<0.05);治療后,治療組患者ESR、NLR及血清SAA、PCT水平低于對照組(P<0.05)。結(jié)論 雙黃連注射液聯(lián)合哌拉西林鈉他唑巴坦鈉治療社區(qū)獲得性肺炎效果確切,能有效促進(jìn)患者臨床表現(xiàn)消除及呼吸功能改善,抑制機(jī)體炎癥狀態(tài)及肺部感染程度,利于加快病情緩解,值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Shuanghuanglian Injection combined with piperacillin sodium and tazobactam sodium in treatment of community acquired pneumonia. Methods A total of 86 patients with community-acquired pneumonia admitted to Fengfeng General Hospital of North China Medical and Health Group from October 2020 to September 2023 were selected and divided into control group and treatment group according to random number table method, with 43 cases in each group. Patients in the control group were iv administered with Piperacillin Sodium and Tazobactam Sodium for injection, after fully dissolving 4.5 g of the product with diluent, immediately added it into 5% glucose injection100 mL, each administration time ≥ 30 min, twice daily. Patients in the treatment group were iv administered with Shuanghuanglian Injection on the basis of the control group, added 5% glucose injection250 mL at the weight of 1 mL/kg, once daily. The treatment course of both groups was 7 d. The clinical effects of the two groups were observed, and the disappearance time of clinical manifestations, oxygenation index (OI), CURB-65 score, erythrocyte settlement rate (ESR), neutrophil to lymphocyte ratio (NLR), serum amyloid A (SAA) and procalcitonin (PCT) were compared between two groups. Results After treatment, the total effective rate of the treatment group was 97.67%, which was significantly higher than that of control group (81.40%, P < 0.05). The disappearance time of fever, cough, phlegm, chest pain, and lung rales in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, OI was significantly increased in both groups, but CURB-65 score was significantly decreased in both groups (P < 0.05). After treatment, OI in treatment group was significantly higher than that in control group, but CURB-65 score was significantly lower than that in control group (P < 0.05). After treatment, the levels of ESR, NLR and serum SAA and PCT in both groups were significantly decreased (P < 0.05). After treatment, the levels of ESR, NLR, SAA, and PCT in the treatment group were lower than those in control group (P < 0.05). Conclusion Shuanghuanglian Injection combined with piperacillin sodium and tazobactam sodium has a definite effect in treatment of community acquired pneumonia, and can effectively promote the elimination of clinical manifestations and the improvement of respiratory function, inhibit the inflammatory state of the body and the degree of lung infection, and help accelerate the remission of the disease, which is worthy of clinical promotion and application.

R974

邯鄲市科技計(jì)劃項(xiàng)目（1523108125）